article thumbnail

Shionogi launches Fetcroja in the UK for aerobic Gram-negative bacteria infections

The Pharma Data

Shionogi has announced the launch of its new antibiotic in the UK for the treatment of infections due to aerobic Gram-negative bacteria in patients over 18 with limited treatment options. . Photo by hiromitsu morimoto.

article thumbnail

UMC Utrecht receives grant for microbiota-boosted cancer therapy 

Drug Discovery World

The bacteria in the intestinal tract (‘ microbiota’ ) play an important role in the success of ICI therapy, suggesting that crosstalk between the immune system and bacteria in the intestine can impact the overall anti-tumor T-cell activation status. . These adverse events often present in the intestinal tract as severe inflammation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BioIVT acquires Cypex to boost portfolio  

Drug Discovery World

This technology enables the expression of human drug-metabolizing enzymes in bacteria, without requiring large modifications to the proteins.? . This work goes towards generating in vitro data showing how a candidate drug will be metabolised in the human body, data often included in new drug applications to regulatory agencies. . ?“We

article thumbnail

Risk adjusted net present value: What is the current valuation of Pharma Mar’s Ecubectedin?

Pharmaceutical Technology

Pharma Mar offers in vitro diagnostic products used for detection of virus and bacteria in respiratory infections and human papilloma virus genotypes, among others. Ecubectedin is a small molecule commercialized by Pharma Mar, with a leading Phase II program in Hormone Sensitive Breast Cancer. Buy the model here. over FY2021.

Hormones 100
article thumbnail

How MedFluid is Targeting Antimicrobial Resistance with its Personalized Infection Screening Tool

XTalks

It identifies bacteria using both genotypic and phenotypic assessments within 1.5 Empirical treatment usually gives two to three antibiotics at the same time to suppress unknown bacteria.”. fAST: Automated Bacteria Identification and Multiple Antibiotics Combination Test.

article thumbnail

Combating antimicrobial resistance with a viable alternative to traditional antibiotics

pharmaphorum

Not to mention that traditional antibiotics are designed to attack a broad spectrum of bacteria within the host’s body. These include the harmful bacterial pathogens that cause an infection, but also the beneficial bacteria which are part of the human microbiome and are essential for good health.

article thumbnail

Biologics – The Next Step in Revolutionary Medication

Roots Analysis

It is worth mentioning that in vitro gene expression requires a suitable host for the production of a specific gene product. Notably, biologics have higher success rates than conventional small-molecule drugs owing to lesser off-target toxicity of biologics, which is one of the key reasons of failures in small molecule drugs development.